Atriva repurposes cancer drug candidates to create universal flu treatment

April 26, 2017 Christoph Graener

Dr. Rainer Lichtenberger, CEO of Atriva Therapeutics, a 2015 startup, explains to Mike Ward, head of pharma content at Informa Pharma Intelligence, how his company is taking kinase inhibitors originally developed as cancer treatments to create a drug that can tackle all known and likely future strains of the influenza virus.

Interviewer: Mike Ward – Global Director of Content, Informa Pharma Insights
Interviewee: Rainer Lichtenberger – CEO, Atriva Therapeutics

Previous Article
Seventure Partners predicts bright future for microbiome opportunities

Seventure Partners’ Eric de la Fortelle explains venture capitalist’s EUR 160 billion fund will prosper fro...

Next Article
Celyad VP talks IP issues, development timelines for CAR-T therapies

Georges Rawadi, VP of business development and intellectual property at Celyad, talks about the company's p...